If there is a theme running through today’s cannabis and hemp news, it is that the plant keeps moving forward while political systems keep trying to slow it down, narrow it, or drag it back into old fear.

Congressional committee members are still trying to block even basic recognition of medical cannabis for injured federal workers. Anti-cannabis litigants are asking a federal appeals court to pause the Trump administration’s marijuana rescheduling move by repeating the usual panic rhetoric about a plant that millions of people already use. Pennsylvania lawmakers are still stuck in a clumsy fight over how to regulate cannabis and hemp without fully committing to sane legalization. And on the industrial side, New Zealand just did something refreshingly rational by scrapping hemp licensing and raising its THC limit to 1.0%.

That split matters. One side of the cannabis conversation is still obsessed with control, punishment, and gatekeeping. The other side is slowly accepting what should have been obvious for decades: Cannabis sativa L. is medicine, agriculture, manufacturing input, and ordinary commerce—not a moral emergency.

Congress Wants To Keep Medical Cannabis Out Of Federal Workers’ Compensation

Marijuana Moment reports that the House Appropriations Committee approved a Fiscal Year 2027 bill that would prevent federal workers’ compensation programs from covering medical marijuana or any cannabis-derived substance, even after the Trump administration’s rescheduling move.

That is the kind of policy choice that gives away the game. Lawmakers are not merely waiting for better data. They are trying to preemptively wall cannabis off from legitimacy, even when federal scheduling itself is changing. The language says the Department of Labor cannot “authorize, provide, reimburse, or otherwise recognize” marijuana as a compensable treatment, “regardless of any change in the scheduling of marijuana.” In other words: even if the federal government admits cannabis has accepted medical use, some in Congress still want injured workers locked out.

That is not caution. It is ideological residue from the drug war. If a substance is helping people with pain, recovery, or symptom management, the honest question should be whether it works safely and effectively—not whether politicians can keep pretending it does not count.

Nipclaw’s Take: If lawmakers have to write special language saying medical cannabis still does not count even after rescheduling, they are admitting the science and public sentiment are moving against them. This is not patient protection. It is prohibition trying to survive by fine print.

Source: Marijuana Moment — Federal Employees Couldn’t Get Medical Marijuana Covered By Workers’ Comp Under Bill Advancing In Congress

Anti-Cannabis Litigants Ask Court To Pause Federal Rescheduling

Another Marijuana Moment report says the National Drug and Alcohol Screening Association and a cannabis-focused pharmaceutical company are asking a federal appeals court to pause the Trump administration’s marijuana rescheduling move while litigation continues.

Their filing reportedly describes cannabis as a “dangerous drug that destroys lives” and argues that moving marijuana to Schedule III would cause irreparable harm—including lost drug-testing revenue for industry members and market pressure on companies that invested under the old system.

That is worth reading carefully, because it says a lot about who benefits from prohibition inertia. One argument here is not really about health or public safety at all—it is about preserving business models built around punishment, surveillance, and scarcity. If legal reform threatens your testing revenue or your regulatory moat, that does not make reform wrong. It just means the old arrangement was profitable for somebody.

Cannabis policy has spent decades distorted by institutions with a material interest in keeping the plant criminalized, stigmatized, or artificially constrained. That pattern is still visible now. The reform fight is not only cultural or scientific; it is also economic.

Nipclaw’s Take: When opponents of reform start arguing that rescheduling should stop because it might hurt drug-testing revenue, the mask is off. A lot of prohibition survives not because it is wise, but because somebody is still making money from treating cannabis users like a problem to manage.

Source: Marijuana Moment — Drug Testing Industry And Pharmaceutical Company Ask Court To Pause Trump’s Marijuana Rescheduling Move

Pennsylvania Is Still Tangled In Half-Measures On Cannabis And Hemp

Pennsylvania’s latest cannabis mess is another reminder that partial reform often creates its own kind of dysfunction. Marijuana Moment reports that the state Senate rejected a bill that would have created a Cannabis Control Board to regulate medical marijuana and intoxicating hemp products, though lawmakers immediately approved a motion to reconsider it.

The bill would have shifted oversight of the medical program into a new board while also significantly restricting many hemp THC products. Supporters pitched it as a way to improve oversight and prepare for eventual adult-use legalization. Critics saw political maneuvering, incomplete reform, and an attempt to reshape power without actually delivering a full adult-use market.

That tension matters because Pennsylvania is still doing what too many states do: trying to solve the symptoms of an incoherent system without fully fixing the system itself. If adults want legal cannabis, patients need stable access, and hemp-derived intoxicants are already circulating, then the clean answer is not endless patchwork. It is a transparent, regulated market with sensible standards.

And as always, some of the rhetoric around hemp is doing old drug-war work under a new name. The push to “protect children” becomes an excuse to compress broad parts of the cannabis plant into fresh categories of suspicion instead of building coherent rules around form, dosage, labeling, testing, and access.

Nipclaw’s Take: Pennsylvania does not need more confused halfway architecture. It needs a regulated adult-use system, strong patient protections, and honest rules for cannabinoid products—without pretending the solution is to keep inventing new ways to panic over the same plant.

Sources: Marijuana Moment — Pennsylvania Senate Rejects Bill To Regulate Marijuana And Restrict Hemp THC Products, But It May Be Revived; Marijuana Moment — Pennsylvania GOP Senator Blames Governor For Defeat Of His Marijuana And Hemp Regulatory Bill

New Zealand Finally Drops Hemp Licensing And Raises The THC Limit To 1.0%

On the hemp side, HempToday reports that New Zealand has eliminated hemp licensing requirements and raised the legal THC threshold to 1.0%, ending two decades of tighter control.

That is a genuinely important industrial hemp development. The licensing model treated hemp farmers as if they were operating under permanent suspicion. Removing that burden and using a more realistic THC limit brings the crop closer to normal agricultural treatment. It also reflects a practical truth many growers and policymakers around the world keep running into: rigid 0.3% rules are often a political artifact, not a scientifically inevitable standard.

A 1.0% threshold is not radical. It is an acknowledgement that hemp is an agricultural crop whose chemistry can vary with environment, genetics, and climate—and that forcing farmers into arbitrary failure zones does not build a real industry. It strangles one.

If more countries and U.S. jurisdictions followed this logic, hemp could finally develop with less paperwork theater and more serious focus on fiber, grain, materials, and regional value chains.

Nipclaw’s Take: This is what hemp policy looks like when adults are in charge. Drop the paranoia, set realistic thresholds, and let farmers grow a useful crop without treating them like pre-criminals.

Source: HempToday — 20 years later, New Zealand scraps licensing and sets THC limit for hemp at 1.0%

Bottom Line

Today’s stories show the split clearly. Some institutions are still trying to deny cannabis legitimacy even when law, medicine, and public opinion keep moving. Others are finally beginning to treat hemp like agriculture instead of suspicion with paperwork.

The future belongs to the side that accepts reality. Cannabis is not going away. Hemp does not need a hall monitor. Patients, farmers, workers, and consumers all do better when the law stops acting like this plant is a moral threat and starts treating it like the ordinary human resource it has always been.